These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 31740186)

  • 21. Axillary de-escalation after neoadjuvant chemotherapy for advanced lymph node involvement in breast cancer.
    Capasso K; Mitri S; Roldan-Vasquez E; Flores R; Bhasin S; Borgonovo G; Davis RB; James T
    Am J Surg; 2024 Oct; 236():115893. PubMed ID: 39153469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Residual Axillary Metastases in Node-Positive Breast Cancer Patients After Neoadjuvant Treatment: A Register-Based Study.
    Munck F; Jensen MB; Vejborg I; Gerlach MK; Maraldo MV; Kroman NT; Tvedskov THF
    Ann Surg Oncol; 2024 Aug; 31(8):5157-5167. PubMed ID: 38704502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study.
    Morency D; Dumitra S; Parvez E; Martel K; Basik M; Robidoux A; Poirier B; Holloway CMB; Gaboury L; Sideris L; Meterissian S; Boileau JF
    Ann Surg Oncol; 2019 Dec; 26(13):4337-4345. PubMed ID: 31605348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Preliminary results.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2019 Sep; 30():52-57. PubMed ID: 31500785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Axillary staging using ultrasound-guided fine needle aspiration biopsy in locally advanced breast cancer.
    Oruwari JU; Chung MA; Koelliker S; Steinhoff MM; Cady B
    Am J Surg; 2002 Oct; 184(4):307-9. PubMed ID: 12383889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.
    Donker M; Straver ME; Wesseling J; Loo CE; Schot M; Drukker CA; van Tinteren H; Sonke GS; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg; 2015 Feb; 261(2):378-82. PubMed ID: 24743607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
    Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients.
    Schipper RJ; de Bruijn A; Voogd AC; Bloemen JG; Van Riet YE; Vriens BEP; Smidt ML; Siesling S; van der Sangen MJC; Nieuwenhuijzen GAP
    Eur J Surg Oncol; 2021 Aug; 47(8):1928-1933. PubMed ID: 34030918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer.
    Schipper RJ; Moossdorff M; Nelemans PJ; Nieuwenhuijzen GA; de Vries B; Strobbe LJ; Roumen RM; van den Berkmortel F; Tjan-Heijnen VC; Beets-Tan RG; Lobbes MB; Smidt ML
    Clin Breast Cancer; 2014 Oct; 14(5):315-22. PubMed ID: 24548732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.
    Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM
    Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of sentinel lymph-node biopsy after neoadjuvant chemotherapy in clinically axilla node-negative patients.
    Çelik A; Çalıkoğlu F; Akbaş A; Ercan G; Muhammedoğlu A
    Surg Today; 2024 Sep; 54(9):1022-1030. PubMed ID: 38627281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neo-Adjuvant chemotherapy and its affects to the axilla-Can we safely downgrade axillary surgery to mirror the approach in the breast.
    Batt J; Chambers A; Al-Allak A; Vestey S; Hunt R; Massey E; Fowler C
    Breast J; 2020 Sep; 26(9):1667-1672. PubMed ID: 32767467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Considerations for sentinel lymph node biopsy in breast cancer patients with biopsy proven axillary disease prior to neoadjuvant treatment.
    Qu LT; Peters S; Cobb AN; Godellas CV; Perez CB; Vaince FT
    Am J Surg; 2018 Mar; 215(3):530-533. PubMed ID: 29246403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
    Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy.
    Kang YJ; Han W; Park S; You JY; Yi HW; Park S; Nam S; Kim JH; Yun KW; Kim HJ; Ahn SH; Park S; Lee JE; Lee ES; Noh DY; Lee JW
    Breast Cancer Res Treat; 2017 Nov; 166(2):473-480. PubMed ID: 28766131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Axillary pathologic response after neoadjuvant chemotherapy in locally advanced breast cancer with axillary involvement].
    Jiménez-Ballvé A; Serrano-Palacio A; García-Sáenz JA; Ortega Candil A; Salsidua-Arroyo O; Román-Santamaría JM; Pelayo Alarcón A; Fuentes Ferrer ME; Carreras-Delgado JL
    Rev Esp Med Nucl Imagen Mol; 2015; 34(4):230-5. PubMed ID: 25743035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Computed tomography reconstruction for evaluating response in axillary lymph nodes of breast cancer after neoadjuvant chemotherapy.
    Wang L; Li Y; Li J; Wang T; Xie Y; He Y; Fan Z; Ouyang T
    Clin Transl Oncol; 2021 Feb; 23(2):240-245. PubMed ID: 32519177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can one stop nucleic acid sampling (OSNA) predict nodal positivity following neoadjuvant chemotherapy? A prospective cohort study of 293 patients.
    Batt J; Schrire T; Rayter Z
    Breast J; 2021 Jul; 27(7):581-585. PubMed ID: 33866637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Routine use of standard breast MRI compared to axillary ultrasound for differentiating between no, limited and advanced axillary nodal disease in newly diagnosed breast cancer patients.
    van Nijnatten TJA; Ploumen EH; Schipper RJ; Goorts B; Andriessen EH; Vanwetswinkel S; Schavemaker M; Nelemans P; de Vries B; Beets-Tan RGH; Smidt ML; Lobbes MBI
    Eur J Radiol; 2016 Dec; 85(12):2288-2294. PubMed ID: 27842679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic performance of breast ultrasonography and MRI in the prediction of lymph node status after neoadjuvant chemotherapy for breast cancer.
    Ha SM; Cha JH; Kim HH; Shin HJ; Chae EY; Choi WJ
    Acta Radiol; 2017 Oct; 58(10):1198-1205. PubMed ID: 28350255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.